Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Open-label trial - Wikipedia
Open-label trial - Wikipedia
From Wikipedia, the free encyclopedia
Clinical trial where the treatment isn't hidden

An open-label trial, or open trial, is a type of clinical trial in which information is not withheld from trial participants.[1] In particular, both the researchers and participants know which treatment is being administered.[1] This contrasts with a double-blinded trial, where information is withheld both from the researchers and the participants to reduce bias.[2][3]

Open-label trials may be appropriate for comparing two similar treatments to determine which is most effective, such as a comparison of different prescription anticoagulants,[4] or possible relief from symptoms of some disorders when a placebo is given.[5]

An open-label trial may still be randomized. Open-label trials may also be uncontrolled (without a placebo group), with all participants receiving the same treatment.[4]

References

[edit]
  1. ^ a b "Open label study". National Cancer Institute, US National Institutes of Health. 2020. Retrieved 20 November 2020.
  2. ^ "Double-blind (trial)". Merriam-Webster Medical Dictionary. 2020. Retrieved 20 November 2020.
  3. ^ "Double-blind study". HIV.gov, Office of AIDS Research, US National Institutes of Health. 2020. Retrieved 20 November 2020.
  4. ^ a b Beyer-Westendorf, J.; Buller, H. (2011). "External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?". Journal of Thrombosis and Haemostasis. 9 (11): 2153–2158. doi:10.1111/j.1538-7836.2011.04507.x. ISSN 1538-7933. PMID 21920015.
  5. ^ Ballou, Sarah; Kaptchuk, Ted J.; Hirsch, William; Nee, Judy; Iturrino, Johanna; Hall, Kathryn T.; Kelley, John M.; Cheng, Vivian; Kirsch, Irving; Jacobson, Eric; Conboy, Lisa; Lembo, Anthony; Davis, Roger B. (25 May 2017). "Open versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial". Trials. 18 (1): 234. doi:10.1186/s13063-017-1964-x. ISSN 1745-6215. PMC 5445390. PMID 28545508.
  • v
  • t
  • e
Clinical research and experimental design
Overview
  • Clinical trial
    • Trial protocols
    • Adaptive clinical trial
  • Academic clinical trials
  • Clinical study design
  • Evidence-based medicine
  • Real world evidence
  • Patient and public involvement
Controlled study
(EBM I to II-1)
  • Randomized controlled trial
    • Scientific experiment
    • Blind experiment
    • Open-label trial
  • Adaptive clinical trial
    • Platform trial
Observational study
(EBM II-2 to II-3)
  • Cross-sectional study vs. Longitudinal study, Ecological study
  • Cohort study
    • Retrospective
    • Prospective
  • Case–control study (Nested case–control study)
  • Case series
  • Case study
  • Case report
Measures
Occurrence
Incidence, Cumulative incidence, Prevalence, Point prevalence, Period prevalence
Association
Risk difference, Number needed to treat, Number needed to harm, Risk ratio, Relative risk reduction, Odds ratio, Hazard ratio
Population impact
Attributable fraction among the exposed, Attributable fraction for the population, Preventable fraction among the unexposed, Preventable fraction for the population
Other
Clinical endpoint, Virulence, Infectivity, Mortality rate, Morbidity, Case fatality rate, Specificity and sensitivity, Likelihood-ratios, Pre- and post-test probability
Trial/test types
  • In vitro
  • In vivo
  • Animal testing
  • Animal testing on non-human primates
  • First-in-man study
  • Multicenter trial
  • Seeding trial
  • Vaccine trial
Analysis of clinical trials
  • Risk–benefit ratio
  • Systematic review
  • Replication
  • Meta-analysis
  • Intention-to-treat analysis
Interpretation of results
  • Selection bias
  • Survivorship bias
  • Correlation does not imply causation
  • Null result
  • Sex as a biological variable
  • Category
  • Glossary
  • List of topics
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Open-label_trial&oldid=1336219052"
Categories:
  • Design of experiments
  • Clinical trials
  • Scientific method
  • Research methods
Hidden categories:
  • Articles with short description
  • Short description is different from Wikidata

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id